Oxybutynin

Gelnique, Oxytrol, Oxytrol For Women, Kentera, Oxybutynin Nicobrand (oxybutynin) is a small molecule pharmaceutical. Oxybutynin was first approved as Gelnique on 2003-02-26. It is used to treat dysuria, neurogenic urinary bladder, and urinary incontinence in the USA. It has been approved in Europe to treat urge urinary incontinence. The pharmaceutical is active against muscarinic acetylcholine receptor M1 and muscarinic acetylcholine receptor M3. In addition, it is known to target muscarinic acetylcholine receptor M4, muscarinic acetylcholine receptor M2, and muscarinic acetylcholine receptor M5. Oxybutynin chloride's patent is valid until 2022-06-25 (FDA).